Press Releases
Press Releases
-
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
-
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
-
AntriaBio Announces First Close of Private Placement Transaction
-
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
-
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
-
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
-
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
-
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
-
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
-
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species